Regenerative medicine company Orthocell (ASX:OCC) has received a U.S. patent covering the manufacture of its Celgro collagen-based scaffold for the surgical repair of soft tissue injuries.
This includes the repair of tendon, cartilage, bone and tissue, as well as the delivery of stem cells to relevant surgical sites
The company was previously granted patents for this method in Singapore, China and New Zealand.
Award of the U.S. patent “A Collagen Scaffold for Cell Growth and a method producing the Same” provides protection for its Celgro™ product in the U.S. as it prepares for registrations and commercialisation in that market.
It also strengthens the company’s international intellectual property position.
Celgro boasts superior tissue in-growth and repair qualities, while exhibiting strong mechanical properties which can be tuned to accommodate the needs of the specific tissue repair.
It is also free of cells and DNA and is manufactured in a strict quality controlled cleanroom from Australian sourced raw materials that eliminates disease transmission concerns.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.
